"Triglycerides (the ANCHOR Study)", reported that Vascepa 4 g/day, when added to optimized statin therapy for 12 weeks, significantly reduced median particle concentrations of total very-low-density lipoprotein (VLDL) by 12.2%, total low-density lipoprotein (LDL) by 7.7%, and small LDL particles by 13.5% across the 12 week treatment period, compared with placebo."
The important thing about this is is that Vascepa is reducing the lipoprotein particle concentrations, not the cholesterol..The key concept is particle concentration (ie numbers) represent a true representation of the CVD risk, and are much more important than cholesterol content...One of the problems with statins is they lower cholesterol more than they lower particle counts, and cholesterol is less important.
This could mean that Vascepa was a better treatment than statins...Or at the very least using statins without V was sub optimal treatment..
News 
Market Data 
Discover 
AI
